We are solidifying our commitment to the Australian market with the official launch of Viedoc Australia Pty Ltd., a newly established legal entity set to begin operations on April 1st. Our local expertise in Professional Services and Sales will continue to serve our growing client base.
"Australia has played an important role in our journey over the years. We've seen consistent growth in the region, even without a local team on the ground," says CEO, Mats Klaar. "Now, we’re making that investment—to get even closer to our customers, strengthen partnerships, and ensure we're delivering the support they need, when they need it."
Since 2009, we have supported clients in Australia remotely from our headquarters in Uppsala, Sweden. Despite the ten-hour time difference, we've seen steady adoption of our platform, thanks in part to its intuitive design and reliability.
Recognizing the trust placed in us by Australian companies, we have now established a local team in Melbourne by welcoming industry experts Johan van Wyk, Hana Kazda, and Yolande Faber in Brisbane. Their expertise will help strengthen our collaborations with leading sponsors and CROs in the region, including several ongoing long-term partnerships.
"With long-term collaborations in mind and plenty of exciting growth opportunities ahead, we’ve now taken the next big step—establishing a legal entity in Australia," says Mats Klaar.
Why Australia continues to be a strategic market
The reasons are clear:
- Generous research and development tax incentives
- A world-class healthcare system
- A genetically diverse population
- A strong reputation for ethical research and top-quality clinical data, trusted by both the FDA and EMA
Building on this momentum, we are also bringing our User Group Meeting (UGM) to Australia for the second time, following the success of last year’s event. This gathering offers a unique opportunity for sponsors, CROs, and research professionals to connect, share insights, and explore how our platform continues to drive innovation in clinical trials.
Australia has long been a hotspot for early-phase trials, but its strengths extend far beyond that. With a strong regulatory framework and a history of delivering high-quality clinical data, it remains one of the most attractive locations for research across all trial phases. By establishing Viedoc Australia Pty Ltd. and expanding our local team, we are reinforcing our commitment to the region and positioning ourselves to support the future of clinical research in Australia.
As we expand our business, we remain committed to providing trusted, industry-leading solutions. Learn more about why we’ve been recognized as a Leader in Everest Group's Life Sciences Electronic Data Capture (EDC) PEAK Matrix® Assessment 2024, an evaluation by a leading external review firm.